ArticleDermatology and therapy2024

Phase I Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-858 for Treatment of Glabellar Lines.

Chih-Hung Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.